
• inpart Industry Call for Opportunities

Seeking Late Preclinical Oncology Assets: Small Molecules with IND-enabling Data and Patient Stratification Potential

Cumulus Oncology is seeking **small molecule oncology assets** that are at or near the **IND-enabling stage** and supported by **GLP toxicology data**, a defined **biomarker strategy**, and has potentially started GMP synthesis. In particular, their goal is to identify programs with strong translational relevance and a clear path to early clinical proof of concept.



Approaches of Interest:

- Ideal assets will have a well-characterized mechanism of action and potential for monotherapy or rational combinations
- Assets with defined biomarkers to support patient selection will be prioritized
- Assets attracted to targets that have multi-indication potential are of interest for example, inflammation-driven cancer
 pathways
- . Small molecule assets are of highest interest

Out of Scope:

· Diagnostic-only approaches

Developmental Stages of Interest:

• Opportunities from late preclinical research stage to Phase I stage are within scope. Opportunities that involve novel targets and demonstrate *in vivo* efficacy in solid tumor models.

Submission Information

Submission of one-page, 200–300-word briefs are encouraged, along with any optional supplementary information e.g., relevant publications. **Submissions from academic institutes must be supported by GLP toxicology data.** In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, where any of: partnership (co-funding), licensing and asset purchase are options. Collaboration terms will be tailored on a case-by-case basis based on asset maturity, strategic alignment, and development potential.

Opportunities sought



Spinout companies



Biotech assets

0

Technologies

Submissions

Please submit relevant, non-confidential opportunities to Karla Schramm at kschramm@usf.edu

Deadline: 11th July 2025 - 4:59 pm GMT

Have any questions?
Contact Karla Schramm at kschramm@usf.edu



Cumulus Oncology is Europe's first oncology biotech creation studio, founded and led by a senior team with deep expertise across oncology drug discovery, licensing and business development, IND-enabling studies, and early clinical development. The team has a proven track record of successfully identifying, developing, and commercializing novel cancer therapies. Cumulus combines scientific rigor with commercial insight to efficiently advance high-potential assets in collaboration with global partners.